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Background: Breast cancer is the most frequently diagnosed cancer in women in the United States. Approximately
70% of breast cancers are diagnosed in postmenopausal women. Major clinical trials and experimental studies
showed that aromatase inhibitors are effective against postmenopausal breast cancer. Despite their effectiveness in
reducing tumor recurrence, aromatase inhibitors have adverse effects on the cardiovascular system and increase
osteoporosis and bone fractures. Our study is aimed at investigating the role of natural steroid hormones on serum
cardiovascular and bone resorption markers in an established mouse model mimicking postmenopausal breast
cancer.
Methods: Ovariectomized nude mice were transplanted with MCF-7 breast cancer cells constitutively expressing
aromatase. The mice were treated with different combinations and doses of steroids, [estrogen (25 pg, 40 pg,
100 pg), progesterone (6 ng) and testosterone (50 ng)] along with dehydroepiandrostenedione (100 ug). Serum
levels of HDL, LDL/VLDL, free and total cholesterol, total and bone specific alkaline phosphatase and triglycerides
were analyzed after 5, 10 and 15 months.
Results: Free cholesterol and LDL/VLDL levels in serum were reduced in groups mimicking estrous cycle and
menstrual cycle hormones treatment. HDL cholesterol was increased in all the hormone treated groups except the
estrous cycle-mimicking group. Bone specific alkaline phosphatase was decreased in menstrual cycle levels of
estrogen and progesterone treatment.
Conclusions: All together our results show that use of natural hormones in appropriate combinations have
beneficial effects on cardiac and bone toxicity, along with better tumor reduction than current treatments.
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Breast cancer is one of the most common cancers among
women, with more than one million cases and nearly
600,000 deaths annually worldwide [1]. Breast cancer inci-
dence rates vary markedly among countries. Breast cancer
is the most frequently diagnosed cancer in women in the
United States. Due to the high incidence rate along with
social and cultural considerations, breast cancer ranks
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article, unless otherwise stated.advancement of new preventive strategies, the incidence
of breast cancer has remained the same since 2005 [2].
Approximately 70% of breast cancers are diagnosed in
postmenopausal women [3].
The steroid hormones estrogen and progesterone have
long been thought to play a role in the etiology of breast
cancer. Apart from breast cancer growth, these hormones
also influence various physiological processes. After the
cessation of ovarian function, a significant decrease in the
ovarian hormones estrogen and progesterone leads to a
variety of symptoms known as postmenopausal symp-
toms. The most common symptoms include hot flashes,
night sweats, mood swings, and sleep disturbances. These
symptoms negatively influence a woman’s quality of life.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and lipid metabolism and cardiovascular function [4-7].
To alleviate postmenopausal symptoms, hormone replace-
ment therapy (HRT) is used as a treatment. In particular,
HRT has been shown to alleviate vasomotor symptoms,
aid in the prevention of osteoporosis and improve serum
lipid profiles [8-11].
Despite positive effects of HRT, some exogenous hor-
mones have been shown to increase the incidence of
breast cancer. The Women’s Health Initiative (WHI) study,
which utilized conjugated equine estrogen (0.625 mg per
day) and medroxyprogesterone acetate (2.5 mg per day),
revealed a 24% increased risk for invasive breast can-
cer [12], with no major beneficial effects against car-
diovascular disease, stroke, and thromboembolic diseases
[13]. These findings resulted in a 63% reduction of
HRT use within 3 months after the WHI publication.
However, recent analyses of the WHI data have shown
that estrogen replacement therapy alone (without medrox-
yprogesterone acetate) actually decreased the risk of
breast cancer [12].
Aromatase inhibitors (AIs) are widely used for the ad-
juvant treatment of postmenopausal breast cancer, gen-
erally prescribed for five years at the conclusion of
surgery, chemotherapy and/or radiation treatment. AIs
target the aromatase enzyme, which converts adrenal an-
drogens to estrogens. After the Arimidex, Tamoxifen,
Alone or in Combination (ATAC) trial showed AIs are
equally effective to tamoxifen, the FDA approved AIs as a
first-line endocrine therapy for preventing recurrence of
hormone-positive postmenopausal breast cancer [14-18].
However, several observational and meta-analyses re-
vealed that AIs used for the prevention of postmenopausal
breast cancer reduce cancer recurrence but also have ser-
ious side effects on bone and the cardiovascular system.
AIs cause severe joint pain, hip fracture, increased osteo-
porosis risk, and musculoskeletal pain. Loss of learning
and memory function is also an important adverse effect
associated with AI treatment that can lead to dementia at
later stages [19,20]. In a large cohort study using 8,769
breast cancer patients, approximately 51% of the patients
discontinued their adjuvant hormonal therapies including
tamoxifen and AIs due to the adverse side effects [21].
Therefore, it is imperative to find alternative treatment
regimens with fewer unfavorable side effects for postmen-
opausal breast cancer patients.
From the available literature and published data, it is
clear that currently used treatments reduce breast cancer
recurrence but also have serious undesirable side effects
that limit their usefulness. In this study, we aimed to de-
velop hormone treatments that will provide similar or
improved survival rates compared with the drugs used
currently, but without the harmful and undesirable side
effects.Methods
Animals
Female athymic nude mice were obtained from Harlan
Laboratories™ (San Diego, CA). Animals were housed in
groups in a pathogen-free environment under controlled
light and humidity conditions, and received food and water
ad libitum. The mice were ovariectomized at 10 weeks of
age. One week later, mice received transplants of MCF-7
cells stably transfected with the human aromatase gene. Each
experimental group had 15 animals and when necessary
for validation, experiments were repeated. All procedures
followed the Animal Care and Use Committee guidelines
of Texas Tech University Health Sciences Center.
Cell culture and xenograft transplantation
MCF-7 cells stably transfected with the human placental
aromatase gene (MCF-7-ARO) were cultured in Eagle’s
minimum essential media containing 10% fetal bovine
serum and antibiotics. Subconfluent MCF-7-ARO cells
were trypsinized and suspended in collagen matrix solu-
tion (85% collagen and 15% neutralizing buffer) to make
a concentration of 3 107 cells/ml. At 11 weeks of age,
ovariectomized mice were inoculated with MCF-7-ARO
cells. Each mouse was inoculated with 0.1 ml cell sus-
pension in both flanks (~3 106 cells/site). Tumor growth
was determined by measuring tumor volume using the
formula 4/3 r1
2r2, where r1 is the minor radius and r2 is
the major radius.
Hormone treatments
Ten-week-old mice were ovariectomized and randomly
separated into 8 groups consisting of 15 animals per group.
Mice in all groups were inoculated with MCF-7-ARO cells
at 11 weeks of age. As shown in Figure 1, the mice were ei-
ther exposed to hormones continuously, or in a treatment
mimicking the estrous cycle in the mouse (because we were
using a mouse model) or human (because the implanted
tumor tissue was of human origin). Throughout the experi-
ments, ovariectomized animals received 0.1 mg dehydro-
epiandrosterone (DHEA) daily via subcutaneous injection,
to allow the aromatization process which is responsible for
much of postmenopausal hormone production and which
is attacked by aromatase inhibitors. Estrogen (E), progester-
one (P), and testosterone (T) were packed in individual si-
lastic tubes. Dosages were adjusted such that they would
result in 40 or 100 pg/ml estradiol, 6 ng/ml progesterone,
and 50 ng/ml testosterone in circulation. Anastrozole, an
aromatase inhibitor, which is used as an adjuvant therapy
in postmenopausal breast cancers, was administered via
subcutaneous injections (60 μg daily/mouse).
Running wheel experiments
Mice were housed in groups of 3 animals per cage. A
running wheel was placed in the cage of experimental
Figure 1 Schematic representation of experimental setup. One hundred and twenty female, nude mice were ovariectomized at 10 weeks of
age. After a week MCF7-ARO cells were injected into the flanks (~3 × 106 cells/site) and the animals were separated into 8 groups (n = 15). All the
animals received 0.1 mg DHEA as daily subcutaneous injection. Ovariectomized control group animals did not receive any additional treatment,
AI group animals received 60 μg anastrozole as subcutaneous injection for 7 weeks, E + P (40/6) group animals were implanted with E and P pellets
that results in 40 pg E and 6 ng of P in circulation, E + P (100/6) delivers E and P to achieve 100 pg E and 6 ng P in circulation, E + P + T group animals
received T pellets along with E and P pellets to achieve serum concentration of E-100 pg, P-6 ng and T-50 ng. AI + E + P group animals received 60 μg
anastrozole as subcutaneous injection, for 7 weeks and E and P pellets to release E-100 pg and P-6 ng in circulation. Estrous group animals received
E pellets releasing 25 pg of E in circulation and additionally they received 0.1 μg of E at day 1 and 0.5 mg of P at day 3 as a subcutaneous injection,
to mimic estrus cycle. The estrus cycle treatment was repeated every 5 days, till the end of the experiment. Menstrual group animals were implanted
with E pellets releasing 100 pg of E in circulation and 1 mg of P as a subcutaneous injection at day 14 through day 28 and the procedure was repeated
every month to mimic human menstrual cycle. A set of 3 mice per group was terminated at 5, 10 and 15-month time points and remaining 6 animals
were observed until ~30 months. A survival surgery was performed to remove tumors if they reach 500 mm3 in size.
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measure of physical activity. The number of revolutions
was monitored using a sensor connected to a computer.
Because 3 mice were housed per cage, the average num-
ber of rotations per hour was calculated based on the
total revolutions per hour divided by the number of
mice in the cage.
Morris water maze tests
The Morris water maze was used to measure cognition
and the spatial learning ability of the animals [22]. Briefly,
the water maze was a circular pool (120 cm in diameter,40 cm in height) with water filled to 2 cm and maintained
at a temperature of 20 ± 2C. A plastic square platform,
14 cm 14 cm, was placed 1 cm below the water level.
Each mouse received five training trials (50 seconds
each) for 7 consecutive days. During the first 2 days, we
used a visible platform, but we used a hidden platform for
all other days. Latency to escape from the water maze
(the time to find the submerged platform) was calcu-
lated for each trial within the 50-second period. Swimming
distance and speed were also analyzed. The percentage
of mice that reached the platform in each group was
calculated.
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Animals were euthanized at different time points and
serum was separated from whole blood collected and
used for biochemical analyses. Serum levels of total chol-
esterol, free cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL), very-low-density lipopro-
tein (VLDL), and triglycerides were measured using
commercially available kits (Biovision, Milpitas, CA).
Total and bone-specific alkaline phosphatase analyses
Determination of serum alkaline phosphatase (ALP) levels
reflects the bone health of animals [23]. ALP enzymatic
activity was quantified using a p-nitrophenylphosphate
(pNPP) colorimetric assay kit (Biovision, Milpitas, CA).
Serum bone-specific alkaline phosphatase levels were de-
termined using an ELISA kit (Cosmo Bio, Carlsbad, CA).
Statistical analysis
The data are expressed as mean ± SEM. The Mann–
Whitney test or Student’s t test was used to analyze dif-
ferences between the groups using the GraphPad Prism
6 software package. Any value that was P < 0.05 was con-
sidered statistically significant.
Results
Effect of the aromatase inhibitor and hormones on
mammary tumor growth
To mimic the postmenopausal breast cancer condition,
tumor xenografts were established using aromatase-
overexpressing MCF 7 cells in ovariectomized mice. Tumor
xenografts in the control ovariectomized mice were rela-
tively fast growing and reached sizes of 500 mm3 (8 mm
diameter) 12 weeks after transplantation (Figure 2a). Mice
treated with anastrozole showed slower tumor growth
during the active phase of treatment (designed to replicate
the standard 5-year treatment protocol in women), but
growth accelerated upon cessation. AI-treated tumors
reached 490 mm3 after 16 weeks. Treatment of the ana-
strozole group with continuous E (100 pg/mL) plus P
(6 ng/mL) also showed similar effects on the growth of
tumor xenografts (500 mm3 16 weeks after tumor trans-
plantation) (Figure 2a). Combination of E (40 pg/mL) and
P (6 ng/mL), along with estrous levels of hormones treat-
ment, did not markedly influence tumor xenograft growth
compared with ovariectomized controls (Figure 2a).
Ovariectomized control and estrous levels of hormone
treatment group animals reached ~520 mm3 at 13 and
15 weeks respectively, whereas tumor xenografts in E
(40 pg/mL)- plus P (6 ng/mL)-treated animals reached
sizes of ~550 mm3 as early as 12 weeks after transplant-
ation (Figure 2a).
There was a remarkable reduction in the growth of xe-
nografts in animals that received testosterone in addition
to E and P. Furthermore, animals that received cyclicalmenstrual levels of hormone treatment also had reduced
tumor growth. These tumors were relatively slow growing
and reached sizes of 380 mm3 and 420 mm3 19 weeks after
xenograft transplantation (Figure 2a). Other slow growing
tumor xenografts were observed in the E (100 pg/mL) plus
P (6 ng/mL) treatment group, with a latency of 17 weeks
to reach a size of 480 mm3 (Figure 2a).
Effect of the aromatase inhibitor and hormones on body
weight
Addition of E (100 pg/mL) plus P (6 ng/mL), along with
anastrozole treatment, markedly reduced the body
weight gain of mice compared with mice treated with AI
alone (approximately 16% reduction compared with the
AI-treated group) (Figure 2b). This outcome was consid-
ered positive because as for humans, weight gain post-
ovariectomy results in wide-ranging sequelae in the
murine model, with diabetic syndromes and resulting
paw and forelimb infection a notable example. Ovariec-
tomized controls and anastrozole-treated animals exhib-
ited maximum body weight gain of all groups, and there
were no significant differences between these two groups
of mice (Figure 2b). Animals that received estrous levels
of E plus P in a cyclic manner had the lowest weight
gain. The estrous level of E plus P treatment was effect-
ive in reducing the final body mass by 31% compared
with ovariectomized control animals (Figure 2b). Ovari-
ectomized mice treated with a combination of E, P, and
T had significantly reduced body weights compared with
ovariectomized control mice (Figure 2b). Overall, all
hormone treatments reduced the weight gain and final
body weight of animals compared with ovariectomized
controls and anastrozole-treated mice.
Effect of the aromatase inhibitor and hormones on
running wheel performance
Because physical activity reflects general health and well-
ness, we also observed the physical activity of the animals.
Running wheel revolutions per hour were monitored as
an indicator of physical activity. AI-treated mice had re-
duced numbers of revolutions per hour on the running
wheel compared with ovariectomized control mice indi-
cating that AI treatment induces a comparatively seden-
tary life style. Supplementation of E + P with AI treatment
increased the running wheel performance of mice to con-
trol ovariectomized levels at 5 and 10 months (Figure 3a,
see Additional file 1: Figure S1a). Animals treated with E
(40 pg/mL) plus P (6 ng/mL), E (100 pg/mL) plus P (6 ng/
mL), and E plus P plus T significantly increased running
wheel activity compared with control ovariectomized mice
(Figure 3a). Cyclic treatment with hormones represent-
ing estrous and menstrual cycles also improved run-
ning wheel performance compared with ovariectomized
mice after 5 and 10 months (Figure 3a, see Additional
Figure 2 Effect of hormones on MCF7-ARO tumor xenograft growth and body weight in female nude mice. a) Mice were treated with
AI and hormones according to the experimental setup described in Figure 1 in Methods. Tumor growth was measured twice a week and
tumor volume was calculated using the formula 4/3 r1
2r2, where r1 is the minor radius and r2 is the major radius. Tumor growth was rapid in
ovariectomized control and mice received E + P (40/6), whereas E + P + T (100/6/50) and E + P (Menstrual) treatment reduced the tumor growth
drastically. b) Body weight of the animals shows toxicity of the treatment and general health of the animals. Ovariectomized control and AI
treated mice gained weight constantly throughout the experimental period. E + P (Estrus) and E + P (100/6) group animals showed least weight
gain compared to other groups. All values are expressed as mean and for the clarity of the bar-diagram the error bars (representing SD)
were removed.
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of animals showed similar performance on the running
wheel, but with a slight increase in the steady state level
of the hormone treatment groups (See Additional file 1:
Figure S1b).
Water maze
To access spatial learning ability, we used water maze
experiments. Initially, all animals showed comparatively
equal cognitive behavior with 8 to 16% of animals reach-
ing the platform (Figure 3b). After the trials, mice treated
with AI showed the least improvement in spatial learn-
ing memory because only 34% of animals succeeded
in reaching the platform whereas 54% of ovariectomizedcontrols reached the platform (Figure 3b). This find-
ing may indicate that AI reduces cognition and spatial
learning ability. Supplementation with E plus P and
AI improved cognition and spatial learning ability to
54% after trials, which showed a positive effective of
E and P treatment (Figure 3b). The most effective
hormone treatment combination was E plus P plus T
in steady state and cyclic hormone treatment mimick-
ing estrous cycles, which showed ~80% improvement
in the learning memory of mice (Figure 3b). Further,
approximately 70% of animals reached the platform in
the E (40 pg/mL) plus P (6 ng/mL), E (100 pg/mL)
plus P (6 ng/mL), and menstrual levels of hormone-
treated groups (Figure 3b).
Figure 3 Effect of hormones on physical activity and cognitive skills. a) Voluntary running wheel performance shows the physical activity
and desire to perform exercise. Revolutions per hour reflect the average physical activity of the animals. AI treatment showed reduced voluntary
physical activity whereas E + P + T treatment showed significantly increased desire towards physical activity. E + P (100/6), E + P (Estrus) and E + P
(Menstrual) groups also showed significantly improved physical activity compared to AI treated group. b) Cognitive function or spatial learning
memory of the mice was tested using Morris water maze. All group mice showed similar cognitive ability during initial training. After training,
mice in AI treatment group showed least improvement and E + P + T group mice showed better cognitive function than other groups. Since,
all 5, 10 and 15-month time points showed similar trend, 10-month time point was taken as a representative result. All values are expressed as
Mean ± SD and p≤ 0.05 was considered statistically significant. *- represents significant difference between AI treatment and other hormone
treatments, #- represents significant difference between ovariectomized control and AI treatment.
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Serum lipid and lipoprotein levels were measured to
evaluate the effect of AI and hormone treatments on the
cardiovascular health of mice. After 5 and 10 months,
serum triglyceride levels were decreased in the AI treat-
ment group compared with the ovariectomized control
group. Significant increases in triglyceride levels were
observed in E (40 pg/mL) plus P (6 ng/mL), E (100 pg/mL)
plus P (6 ng/mL), and the estrous and menstrual cycle
levels of hormone treatment groups compared with ovari-
ectomized controls (Figure 4a). After 15 months of hor-
mone exposure, the elevated triglyceride levels returned tothe levels in ovariectomized controls in E (40 pg/mL) plus
P (6 ng/mL), E (100 pg/mL) plus P (6 ng/mL), and estrous
and menstrual cycle levels of hormone treatment groups
(See Additional file 2: Figure S2b). The E plus P plus T
combination treatment showed no difference in triglycer-
ide levels at the 5-, 10-, or 15-month time point (Figure 4a,
see Additional file 2: Figure S2a,b). Estimation of free and
VLDL/LDL cholesterol levels in serum revealed that AI
treatment remarkably increased the levels of these lipids,
whereas the addition of E plus P along with AI significantly
reduced free cholesterol and VLDL/LDL levels compared
with the AI-treated group (Figure 4b,c). The same trend
Figure 4 Effect of hormones on serum lipid and lipoprotein levels. a) Total serum triglyceride content was significantly increased in E + P
(40/6), E + P (100/6), E + P (Menstrual) and E + P (Estrus) groups. b) Free cholesterol levels were increased significantly in mice treated with AI
compared to ovariectomized control animals. E + P + T treatment showed highly significant reduction compared to ovariectomized control and
AI treatment. Other hormone treatments lowered the free serum cholesterol significantly, except AI + E + P. c) VLDL/LDL cholesterol levels were
significantly increased in AI treatment whereas, the combination of various hormone treatments reduced the VLDL/LDL level significantly. d) Serum
HDL cholesterol levels were increased significantly in all hormone treated groups compared to AI treatment. Since, all 5, 10 and 15-month time points
showed similar trend, 10-month time point was taken as a representative result. All values are expressed as Mean ± SD and p≤ 0.05 was considered
statistically significant. *- represents significant difference between AI treatment and other hormone treatments, #- represents significant difference
between ovariectomized control and AI treatment.
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see Additional file 3: Figure S3 a-d). The highest reduc-
tion in cholesterol levels (both free and VLDL/LDL) was
observed in E plus P plus T treatment group. Both men-
strual and estrous levels had similar effects on reducing
the free and VLDL cholesterol in circulation (Figure 4c &
see Additional file 3: Figure S3 c,d). HDL, the “good chol-
esterol”, was significantly reduced in AI-treated animals
after 15 months, indicating an increased risk for cardio-
vascular diseases (See Additional file 4: Figure S4 b). Com-
bination of AI and E plus P treatment returns the levels of
HDL to ovariectomized control levels (Figure 4d & see
Additional file 4: Figure S4 a). Treatment with E plus P
plus T increased serum HDL cholesterol levels compared
with ovariectomized controls and could be effective in re-
ducing the risk of cardiovascular diseases (Figure 4d & see
Additional file 4: Figure S4 a,b). Both the cyclic levels of
hormone treatments increased HDL cholesterol compared
with ovariectomized levels after 5 months (See Additional
file 4: Figure S4 a). These effects improved and weresignificant at the 10- and 15-month analyses (Figure 4d &
Additional file 4: Figure S4 a,b).
Serum bone formation markers
Analyses of total ALP levels revealed that there was no
marked difference in the activity of total ALP in all groups
at each time point (Figure 5a & see Additional file 5:
Figure S5 a,b). Bone-specific ALP activity assays showed
a significant reduction in activity in the AI-treated mice
(Figure 5b). Because bone-specific ALP is considered
a marker for bone formation, our results indicate that
AI treatment negatively influences bone formation. The
combination of hormones plus AI treatment significantly
increased the activity of bone-specific ALP compared with
the AI-treated group (Figure 5b & see Additional file 5:
Figure S5 c,d). The steady state [E (40 pg/mL) plus
P (6 ng/mL), E (100 pg/mL) plus P (6 ng/mL), and E plus
P plus T] and cyclic (estrous and menstrual) hormone
treatments showed increased bone-specific ALP activity in
serum compared with ovariectomized controls. A similar
Figure 5 Effect of hormones on total and bone specific alkaline phosphatase (ALP). a) There was no significant change in the level of total
ALP was observed at 10 months time point. b) Bone specific ALP levels were increased significantly in combination of hormone treatments.
AI treatment reduced the bone specific ALP levels in the serum showing reduced bone formation process. Since, all 5, 10 and 15-month
time points showed similar trend, 10-month time point was taken as a representative result. All values are expressed as Mean ± SD and
p≤ 0.05 was considered statistically significant. *- represents significant difference between AI treatment and other hormone treatments,
#- represents significant difference between ovariectomized control and AI treatment.
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points (Figure 5b & see Additional file 5: Figure S5 c,d).
Discussion
Anti-estrogen therapies are currently the standard treat-
ment for estrogen receptor-positive breast cancer recur-
rence. However, AIs are known to reduce bone mineral
density, increasing risk of osteoporosis, and their side ef-
fect profile leads to a high discontinuation rate [21].
The current study was performed to investigate hormo-
nal therapeutic regimens that inhibit breast tumor growth
without negative effects on cardiovascular and bone for-
mation processes. The ultimate goal of the study was to
develop a postmenopausal hormone treatment regimenthat blocks the growth of breast cancer while enhancing
overall health and quality of life.
The use of hormone replacement therapy for post-
menopausal symptoms has been the subject of debate
for the past two decades. Studies over that time have re-
vealed a risk-benefit profile that varies by type of hormone,
time since menopause, and organ/system in question [24].
In addition, the dose, duration, and mode of administra-
tion of hormones are important factors in determining the
efficiency and beneficial function of a particular treatment
[25,26]. However, current standard of practice considers
hormones of any type absolutely contraindicated after
hormone-receptor-positive breast cancer, with the as-
sumption being that hormones “throw fuel on the fire” of
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treatment is to block remaining estrogens with aromatase
inhibitors, the exact opposite.
Yet hormones have myriad effects throughout the body,
effects which influence survival and quality of life as much
as breast cancer recurrence does or more. We explored a
radical hypothesis: Could an optimal choice of hormones
lead to improved survival factors and quality of life enough
to outweigh any negative effect on tumor recurrence?
In our experiments, we used steroids in their bioidenti-
cal form, as these hormones have been shown to possess a
more positive risk-benefit profile than synthetic hormones
which have been molecularly altered for patentability or
oral bioavailability [27-30]. The first question we sought
to address was influence on overall health of an optimal
hormone regimen. In the landmark Women’s Health
Initiative study, a negative risk-benefit profile was seen
with oral equine estrogens and oral synthetic medroxypro-
gesterone acetate (PremPro), a drug combination based
on an estrogen formulation first approved in 1942 and
which continues to dominate the market in English-
speaking countries. We therefore chose estradiol and pro-
gesterone delivered non-orally, as is commonly used in
southern European countries and increasingly in English-
speaking countries as well, based on an extensive literature
indicating more favorable global risk-benefit profile [31].
Our results show that the right combination of hormone
treatments is essential to achieving the desired effect on
postmenopausal symptoms and the risks associated with
osteoporosis and cardiovascular disease (CVD). E plus P
plus T treatment was associated with increased cognition,
physical activity, and cardiovascular and bone health in
the mouse model, and demonstrates the potential signifi-
cance of hormone treatment in postmenopausal women.
Testosterone is critical to both physical activity and men-
tal health. Testosterone has been shown to be beneficial
to cognitive function and memory. It also functions like
vasodilator and enhances endothelial functions to improve
cardiac health [32,33]. In our study we found that addition
of testosterone along with estradiol and progesterone im-
proves the cognitive function, physical activity and cardiac
health. In agreement with our study, testosterone therapy
has also been shown to reduce breast cancer incidence in
postmenopausal women and breast tumor growth in ani-
mal models [34-37].
Because estrogen-blocking aromatase inhibitors are
the current adjuvant treatment after hormone-sensitive
breast cancer, common sense would lead to the assump-
tion that any treatment containing estrogen itself would
lead to opposite, highly negative impact on tumor growth.
However, this turned out not to be the case. As was the
case for general health markers, maximal reduction in
tumor growth was achieved by E plus P plus T treatment.
In only one group, the lowest-dose E plus P group, didaddition of estrogen result in tumor volumes slightly
worse than control. Our results thus did not confirm the
“throwing fuel on the fire” conception prevalent among
clinicians.
Furthermore, the antitumor effect of AI treatment,
though notable when compared to control, did not excel
when compared to hormone treatment. Treatment with
AI had initial antitumor activity, consistent with the re-
sults of preclinical studies leading to the approval of AIs.
However, three of five hormone treatment regimens pro-
vided similar suppression of tumor volume to the AI
regimen. And with cessation of the AI treatment phase
(chosen to be equivalent to the current clinical standard
of care, 5 years), the antitumor effect of AIs diminished,
leading to a steepened rise in tumor volume, while the
most effective hormone regimens, including E plus P plus
T, continued to more effectively suppress tumor volume.
A frequent criticism of studies in a mouse model is
that they may have limited utility in predicting eventual
clinical outcomes. Anticipating this objection, we de-
signed our study to exactly mimic conditions such as dose
and length of treatment used in pre-approval studies of
anastrozole (Arimidex®), a leading aromatase inhibitor
currently on the market. These murine-model results were
seen to accurately predict outcomes later seen in large
clinical trials such as the ATAC (Arimidex, Tamoxifen,
Alone or in Combination) trial and were part of the basis
for approval of anastrozole [38,39].
Although an E plus P plus T regimen performed better
in our study than AIs (the current standard of care) on
measures of both tumor growth and general health, con-
siderable momentum, as well as market forces, works
against a reversal in treatment practice from hormone
inhibitors to hormones. We therefore sought to deter-
mine whether addition of optimal hormones could im-
prove quality of life and general health indicators when
added to—instead of substituting for—AI treatment,
without worsening tumor outcomes. Our results indicated
the viability of this approach. When added to AIs, estra-
diol and progesterone significantly improved the general
health of the animals as measured by cardiac and bone
health markers (although positive impact of hormones on
cardiac and bone health markers was not as marked when
added to AIs as when used alone), without promoting
breast tumor growth. We discuss possible explanations for
this seeming paradox—improved general health but lack
of tumor stimulation—below.
Aromatase classically converts C19 steroids (androgens)
to C18 steroids (estrogens) with the addition of a hydroxyl
group. Because it has a wide range of substrate specifi-
city, it accepts DHEA as a substrate and converts it to
estrogens [40,41]. Estrogen, which is predominantly pro-
duced in postmenopausal women by the aromatization of
DHEA, selectively activates ERα [42,43]. Aromatase has
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stroma in postmenopausal women [44,45]. AIs inhibit aro-
matase and reduce the conversion of androgens to estro-
gens in postmenopausal breast cancer patients.
However, this inhibition is not reliably effective long-
term because many patients develop resistance to AI treat-
ment [46-48]. Furthermore, inhibiting aromatase in tissues
outside the breast is associated with a variety of negative
sequelae in joints, bone, and other tissues [49-53]. Our
data indicate that an optimal dose of estradiol and proges-
terone can overcome effects on bone, cardiovascular, and
cognitive health. Furthermore, the addition of testosterone
along with estradiol and progesterone enhances the benefi-
cial effects.
Large observational studies suggest estrogens have a
cardioprotective effect [13,54,55]. Abnormal serum lipid
levels have been associated with an increased risk for
CVDs [13,54]. Low HDL and high LDL levels in serum
are mainly attributed to an increased risk of CVDs. Sev-
eral clinical and experimental studies indicate that estra-
diol treatment is beneficial to the heart by reducing LDL
levels and increasing HDL levels in circulation [56-58].
Based on epidemiological studies, CVDs are prevalent in
postmenopausal women, and serum concentrations of
estrogen are inversely associated with CVD risk [59]. Es-
trogen replacement therapy initiated within 5 years after
menopause has a beneficial effect on cardiovascular risk
factors, but not if the therapy is begun later [60]. Natural
hormone 17-b estradiol was more effective in reducing
CVD risk factors than conjugated equine estrogens, and it
is also affected by an oral or transdermal route of delivery
[61]. Taking all of these factors into account, the cellular
mechanism of estradiol-induced cardioprotection involves
the contribution of several factors including time of ad-
ministration, type of hormone administered, and mode of
administration. Our data demonstrate that administration
of hormones immediately after ovariectomy results in im-
proved cardiac health, in agreement with data from clin-
ical studies.
The role of progesterone versus synthetic progestins in
cardiovascular health is the subject of much debate. The
WHI study demonstrated increased atherosclerosis upon
the use of synthetic progestins [13,62,63]. In a long-term
randomized study that accessed and compared the effects
of synthetic progestins and progesterone on serum lipids,
synthetic progestins negatively influenced the beneficial ef-
fect of estrogens by lowering serum HDL levels [55]. Pro-
gesterone, in contrast, has been shown to support the
cardioprotective actions of estrogen in several other studies
[64-70]. Our results indicate that estrogen and progester-
one improve the serum lipid profile and reduce the risk of
CVDs in a postmenopausal breast cancer mouse model.
Osteoporosis is a major concern in postmenopausal
women. Several studies have shown that estradiol increasesbone formation and prevents osteoporosis [71,72]. Simi-
larly, depletion of estrogen resulted in osteoporosis, sup-
porting the notion that estrogens are important for bone
formation [73,74]. Clinical studies have indicated that
progesterone treatment helps maintain bone mass [75-77].
Progesterone supports bone formation by preventing
glucocorticoid-induced bone loss [54]. Several animal
and human studies have demonstrated progesterone’s
positive effect on bone formation as well as inhibition of
bone resorption [76-78]. Studies evaluating estrogen and
progesterone supplementation suggest estrogen and pro-
gesterone have distinct but complementary roles in bone
maintenance [75-77,79]. The addition of testosterone
positively influences bone mass by preventing urinary cal-
cium loss. Our findings demonstrate that the addition of
hormones along with AI treatment is beneficial for bone
health in postmenopausal women.
Our data on physical activity, cognition, and spatial
learning clearly demonstrate the importance of hormones
in addition to AIs for breast cancer treatment. Cyclical ad-
ministration of hormones appears to have a slightly better
effect versus administration of steady levels of hormones.
It is interesting that the addition of testosterone has a sig-
nificant positive impact on all aspects that were studied in
this investigation.
Conclusions
In summary, our results indicate that the use of appro-
priate combinations of natural hormones along with, or
instead of, classical breast cancer treatments is beneficial
against postmenopausal symptoms and improves cardiac
and osteoporotic health in the mouse model. The nat-
ural hormone combinations tested in this study provide
evidence for a better alternative to standard aromatase
inhibitor treatment following breast cancer in women.Additional files
Additional file 1: Figure S1. Effect of hormones on physical activity.
Running wheel performances of mice at 5 and 15-month time points.
All values are expressed as Mean ± SD and p ≤ 0.05 was considered
statistically significant. *- represents significant difference between AI
treatment and other hormone treatments, #- represents significant
difference between ovariectomized control and AI treatment.
Additional file 2: Figure S2. Effect of hormone treatments on serum
triglycerides. Serum triglycerides levels at 5-month time point showed
similar trends compared to 10-month time point. At 15th month the level
of triglycerides were similar in all the groups. All values are expressed
as Mean ± SD and p ≤ 0.05 was considered statistically significant.
*- represents significant difference between AI treatment and other
hormone treatments, #- represents significant difference between
ovariectomized control and AI treatment.
Additional file 3: Figure S3. Effect of hormone treatments on serum
free cholesterol and VLDL/LDL cholesterol. The level of free cholesterol
was reduced in the E + P (100/6), E + P + T, E + P (Menstrual) and E + P
(Estrus) groups in both 5 and 15 month time points. *- represents
significant difference between AI treatment and other hormone treatments,
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http://www.rbej.com/content/12/1/66#- represents significant difference between ovariectomized control and AI
treatment.
Additional file 4: Figure S4. Effect of hormone treatments on serum
HDL cholesterol. The level of free cholesterol was reduced in the AI
treatment but increased in other hormone treatments in both 5 and
15-month time points. *- represents significant difference between
AI treatment and other hormone treatments, #- represents significant
difference between ovariectomized control and AI treatment.
Additional file 5: Figure S5. Effect of hormones on total and bone
specific ALP. Levels of ALP in all the groups were similar in all the time
points. Bone specific ALP levels were increased in all the hormone treated
groups. *- represents significant difference between AI treatment and
other hormone treatments, #- represents significant difference between
ovariectomized control and AI treatment.
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